Phase I Evaluation of Vamorolone Pharmacokinetics, Safety, and Pharmacodynamics in Healthy Male Volunteers for Duchenne and Becker Muscular Dystrophy

The primary objective of this study is to evaluate the pharmacokinetics and safety profile of **vamorolone** in healthy male participants. This is clinically relevant as it provides foundational data on how the drug is absorbed, distributed, metabolized, and excreted, which is crucial for determining appropriate dosing regimens and ensuring patient safety in future studies targeting **Duchenne muscular dystrophy** and **Becker muscular dystrophy**. No secondary objectives are specified for this study.

The clinical trial involves **healthy male volunteers** with an intended indication for Duchenne muscular dystrophy and Becker muscular dystrophy. The study population is composed exclusively of males, with an age range of 18 to 44 years. Participants are selected based on their general health status, ensuring they are free from significant medical conditions that could interfere with the study outcomes. The trial does not include vulnerable populations. The sponsor has not provided information regarding the total number of participants. Lifestyle considerations such as diet, physical activity, and habits are not specified in the available data. Key inclusion or exclusion criteria are not detailed by the sponsor.

The clinical trial is designed as a **Phase I** study to evaluate the pharmacokinetics, safety, and tolerability of vamorolone in healthy male participants. The trial is intended to gather data relevant to the treatment of **Duchenne muscular dystrophy** and **Becker muscular dystrophy**. The study employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial is from May 15, 2024, to June 29, 2024, with participant involvement expected to last throughout this period unless early termination criteria are met.

Participants will undergo a sequence of study visits, beginning with an inclusion visit, which serves as a screening to confirm eligibility based on predefined criteria. This is followed by a series of follow-up visits, scheduled to monitor the participants' response to the investigational product and to assess any adverse events. The end-of-study visit will conclude the trial for each participant, during which final assessments will be conducted to gather comprehensive data on the investigational product's effects. The expected length of participant involvement is aligned with the trial's overall duration, but participants may be withdrawn early if they experience significant adverse effects or if they fail to comply with the study protocol.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment protocols accurately.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 15, 2024, with an estimated end date of June 29, 2024. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The study will adhere to the rigorous standards expected in a Phase 3 trial, focusing on the evaluation of treatment effects in a controlled environment.